

Thank you for joining!
The webinar will begin shortly.



# Advancing Real World Evidence in APAC



Wed, 30 Mar 2022



10am - 11am (SGT)





# Advancing Real World Evidence in APAC



Wed, 30 Mar 2022



10am - 11am (SGT)

## Agenda

Opening '5	Tom Chang, Project manager , APACMed
Paper Introduction '20	<b>Clark Jennings</b> , Managing Director, Asia, C&M International
Panel Discussion and Q&A '30	Moderator: Anh Bourcet Former Chair, Reimbursement WG, APACMed Regional Director, Market Access, Abbott Diagnostics  Guest speakers: Tracey Duffy First Assistant Secretary, Medical Devices and Product Quality Division, Therapeutic Goods Administration, Australia
	Heather Colvin  Director of Regulatory Affairs, Evidence and Outcomes Policy, Johnson & Johnson
Closing '5	Tom Chang

### APACMed Digital Health Committee

250+ MEMBERS from 75+ COMPANIES: MNCs, SMEs, Start-ups



#### **OUR MISSION**

Support APACMed members across the entire digital health product journey, from regulatory approval to market access and use.

Roberta Sarno

Digital Health Manager

APACMed



Tom Chang
Project Manager
APACMed

Board Sponsor: Elisabeth Staudinger CEO Siemens Healthineers APAC



#### **OUR VALUE**

Share the voice of the industry with the public and private digital health deciders and provide a neutral platform for public-private collaborations on regulatory, cybersecurity, reimbursement, health data, interoperability.







## Panel Discussion

Moderator



Anh Bourcet
Former Chair,
Reimbursement WG,
APACMed

Regional Director, Market Access, Abbott Diagnostics Speaker 1



Tracey Duffy
First Assistant Secretary, Medical
Devices and Product Quality
Division, Therapeutic
Goods Administration, Australia

**Speaker 2** 



Heather Colvin
Director of Regulatory Affairs, Evidence and Outcomes Policy,
Johnson & Johnson

## Speaker Bio

#### Speaker 1



**Tracey Duffy** 

First Assistant Secretary, Medical Devices and Product Quality Division, Therapeutic Goods Administration, Australia Tracey Duffy is the First Assistant Secretary of the Medical Devices and Product Quality Division in the Commonwealth Department of Health.

Her Division is part of the Therapeutic Goods Administration and is responsible for medical device regulation including premarket assessment and post market monitoring, Good Manufacturing Practice inspections and Laboratory testing

## Speaker Bio

Heather M. Colvin is the Director of Evidence and Outcomes Policy for Johnson & Johnson MedTech where she works to advance the adoption of innovative evidence approaches including real-world evidence, the science of patient input, and improving diversity and inclusion in clinical evidence. Prior to joining Johnson & Johnson, she worked at the Duke-Margolis Center for Health Policy, the Brookings Institution, the Institute of Medicine (now the National Academy of Medicine), HHS'Office of Global Health Affairs and the National Committee for Quality Assurance.

She holds a Master of Public Policy from Georgetown University and a Bachelor of Arts in Cultural Anthropology from George Mason University

#### **Speaker 2**



**Heather Colvin**Director of Regulatory Affairs, Evidence and Outcomes Policy,
Johnson & Johnson

## Panel Discussion

Moderator



Anh Bourcet
Former Chair,
Reimbursement WG,
APACMed

Regional Director, Market Access, Abbott Diagnostics Speaker 1



Tracey Duffy
First Assistant Secretary, Medical
Devices and Product Quality
Division, Therapeutic
Goods Administration, Australia

**Speaker 2** 



Heather Colvin
Director of Regulatory Affairs, Evidence and Outcomes Policy,
Johnson & Johnson

### What's next?

- Drive country activation initiatives
- Deep-dive into technical elements of the paper
- Run workshops with partners



## Thank you!

For more information please contact:



Roberta Sarno
APACMed Digital Health Manager
Contact: rsarno@apacmed.org



Cindy Pelou


APACMed Digital Health Project Manager
Contact: cpelou@apacmed.org



Tom Chang

APACMed Digital Health Project Manager

Contact: tchang@apacmed.org



Accordingly, APACMed has identified an initial set of recommendations – all of which fall within the broader areas of potential public-private collaboration, listed below – that policymakers and regulators can undertake to aid the evaluation of the RWE ecosystem in national healthcare systems:

- Promote Public-Private Partnerships to Build Awareness, Capacity, and Expertise
- Embrace RWE's Potential to Improve Patient-Centric Healthcare Decision-making
- Enable Access to, and Quality of, Health Data
- Build Technical and Human Capacity
- Promote International Regulatory Collaboration and Harmonization

Download the paper at https://apacmed.org/resources/